Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.65 |
| ▸ | HTR2C | P28335 | 11/20 | 0.65 |
| ▸ | HTR2B | P41595 | 8/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26965676 | 0.91 | HTR2A (0.62) | HTR2AHTR2CHTR2BGPR84CDK2 | |
| SCHEMBL26965719 | 0.84 | HTR2A (0.52) | HTR2AHTR2CHTR2BHTR6TAAR1 | |
| SCHEMBL26965667 | 0.82 | HTR2A (0.67) | HTR2AHTR2CHTR2BHTR6TAAR1 | |
| SCHEMBL26965630 | 0.81 | HTR2C (0.68) | HTR2AHTR2CHTR2BGPR84TAAR1 | |
| SCHEMBL23819793 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BCDK2HTR6 | |
| SCHEMBL23819939 | 0.81 | HTR2A (0.63) | HTR2AHTR2CHTR2BCDK2HTR6 | |
| SCHEMBL23819789 | 0.81 | HTR2A (0.56) | HTR2AHTR2CHTR2BCDK2HTR6 | |
| Hydrochloric Acid SCHEMBL23805218 | 0.80 | HTR2A (0.55) | HTR2AHTR2CHTR2BCDK2HTR6 | |
| Hydrochloric Acid SCHEMBL23805266 | 0.80 | HTR2A (0.55) | HTR2AHTR2CHTR2BCDK2HTR6 | |
| Hydrochloric Acid SCHEMBL23805267 | 0.80 | HTR2A (0.62) | HTR2AHTR2CHTR2BCDK2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090554-A1 | A METHOD OF TREATING DEPRESSION BY IMMUNE MODULATION | MYND LIFE SCIENCES INC (CA) | 2025-03-20 | — | — | US | disclosed |
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | SYNAPTIVE THERAPEUTICS, LLC | 2024-11-07 | — | — | US | disclosed |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | MYND LIFE SCIENCES INC (CA) | 2023-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366638-A1 | PSILOCYBIN ANALOGS FOR TREATING PSYCHOLOGICAL DISORDERS | HTR1B, HTR2B, PNMT | HTR2A 5/4885HTR2C 4/4885HTR2B 2/4885 |
| US-20230405026-A1 | A Method of Treating Depression by Immune Modulation | ABCF1, ABCF2, ABCB4 | HTR2A 377/4885HTR2C 1196/4885HTR2B 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.